
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics Holdings Inc. possesses a promising growth trajectory, highlighted by its expanding manufacturing capabilities through a joint venture with Meiji Pharma, which is set to enhance production efficiency in Japan. The company anticipates significant near-term revenue potential, projected at over $500 million five years post-launch, particularly following the anticipated clinical data readouts in 2025 and the European Commission's recent marketing authorization for its self-amplifying mRNA COVID-19 vaccine, Kostaive. Additionally, reduced execution risk is anticipated from the partnership with CSL Seqirus, leveraging its established global commercialization expertise to drive Arcturus's market penetration and financial performance.
Bears say
Arcturus Therapeutics Holdings Inc. has significantly revised its revenue projections for the upcoming COVID-19 season, with Kostaive revenue estimates slashed from $156.4 million to $11.8 million, reflecting a drastic reduction in anticipated vaccination doses in Japan. The company reported a net loss of $30 million for the fourth quarter of 2024, coupled with an unfavorable financial outlook stemming from rising operating expenses. Furthermore, the stock's valuation remains heavily reliant on the success of its lead asset, ARCT-154, in the face of significant trial and regulatory risks, casting doubt on its ability to sustain operations and achieve future profitability.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares